Unknown

Dataset Information

0

Receptor activator of nuclear factor-?B ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

ABSTRACT: HIV-infected individuals have an increased prevalence of coronary artery disease. Receptor activator of nuclear factor-?B ligand (RANKL) and osteoprotegerin have been postulated as mediators of vascular calcification. 78 HIV-infected men and 32 healthy controls without history of coronary artery disease were prospectively recruited to undergo cardiac computed tomography and computed tomography angiography to assess coronary artery calcium and plaque burden. Soluble receptor activator of nuclear factor-?B ligand was lower in HIV-infected individuals than controls [2.52 (1.08-3.98) vs. 3.33 (2.44-4.64) pg/mL, P = 0.01, median (IQR) respectively]. Soluble receptor activator of nuclear factor-?B ligand was negatively associated with the number of coronary segments with plaque (Spearman ? = -0.41, P < 0.001) and Agatston calcium score (? = -0.30, P < 0.01) in HIV-infected individuals even after adjusting for traditional cardiovascular risk factors.

SUBMITTER: Hwang JJ 

PROVIDER: S-EPMC3766949 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Hwang Janice J JJ   Wei Jeffrey J   Abbara Suhny S   Grinspoon Steven K SK   Lo Janet J  

Journal of acquired immune deficiency syndromes (1999) 20121101 3

HIV-infected individuals have an increased prevalence of coronary artery disease. Receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin have been postulated as mediators of vascular calcification. 78 HIV-infected men and 32 healthy controls without history of coronary artery disease were prospectively recruited to undergo cardiac computed tomography and computed tomography angiography to assess coronary artery calcium and plaque burden. Soluble receptor activator of nuclear  ...[more]

Similar Datasets

Unknown Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors.
| S-EPMC10379842 | biostudies-literature
Unknown Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women.
| S-EPMC6784533 | biostudies-literature
Unknown Involvement of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-induced Incomplete Cytokinesis in the Polyploidization of Osteoclasts.
| S-EPMC4751386 | biostudies-literature
Unknown Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-κB Ligand (RANKL).
| S-EPMC6982798 | biostudies-literature
Unknown Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.
| S-EPMC3190927 | biostudies-literature
Unknown MYC-mediated miR-320a affects receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast formation by regulating phosphatase and tensin homolog (PTEN).
| S-EPMC8810188 | biostudies-literature
Unknown Correction for Ta et al., Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis
| S-EPMC3116411 | biostudies-literature
Unknown Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis.
| S-EPMC5647721 | biostudies-literature
Unknown Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
| S-EPMC4317778 | biostudies-literature
Unknown Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts.
| S-EPMC2775986 | biostudies-literature